Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
14.42
Oct 23 • 3:59 PM ET Dollar change-0.33 Percentage change(-2.24%)
Aftermarket Close
14.42
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
500.36M
Enterprise Value
406.92M
Income
0.53M
Sales
95.42M
Book/sh
3.50
Cash/sh
2.76
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
156
IPO
Oct 23, 2001
P/E
2363.93
Forward P/E
-
PEG
-
P/S
5.24
P/B
4.12
P/C
5.22
P/FCF
28.58
EV/EBITDA
-
EV/Sales
4.26
Quick Ratio
8.95
Current Ratio
9.83
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
0.01
EPS next Y
-0.06
EPS next Q
-0.09
EPS this Y
-357.14%
EPS next Y
67.20%
EPS next 5Y
37.00%
EPS past 3/5Y
- -
Sales past 3/5Y
215.30% 120.21%
EPS Y/Y TTM
-76.27%
Sales Y/Y TTM
35.85%
EPS Q/Q
0.15%
Sales Q/Q
20.60%
Insider Own
7.49%
Insider Trans
0.00%
Inst Own
50.76%
Inst Trans
5.62%
ROA
0.42%
ROE
0.47%
ROIC
0.43%
Gross Margin
87.05%
Oper. Margin
-1.90%
Profit Margin
0.56%
SMA20
-4.77%
SMA50
-9.29%
SMA200
17.85%
Trades
Shs Outstand
34.64M
Shs Float
32.10M
52W High
17.42 -17.22%
52W Low
8.12 77.59%
Volatility
2.78% 3.47%
ATR (14)
0.51
RSI (14)
40.01
Beta
0.60
Rel Volume
0.70
Avg Volume
469.68K
Volume
326,493
Perf Week
2.41%
Perf Month
-10.32%
Perf Quarter
20.77%
Perf Half Y
33.03%
Perf YTD
42.77%
Perf Year
38.92%
Perf 3Y
312.00%
Perf 5Y
43.34%
Perf 10Y
-100.00%
Prev Close
14.75
Price
14.42
Change %
-2.24%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Craig Hallum Buy $18
May-14-24Initiated Stephens Overweight $25
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pennell SandraChief Financial OfficerMar 06 '26Buy9.045,53350,01877,018Mar 06 04:22 PM
Sylvester John RichardDirectorNov 21 '25Buy8.894,38638,99214,936Nov 25 04:15 PM
MICHEL GERARD JCHIEF EXECUTIVE OFFICERNov 11 '25Buy8.5311,50098,049330,834Nov 13 11:53 AM
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.
MSMr. Gerard J. Michel MBA
Chief Operating OfficerDr. Martha S. Rook Ph.D.
M.Sc.Dr. Vojislav Vukovic M.D.
Chief Financial OfficerMs. Sandra Pennell CPA
General CounselMr. David Hoffman J.D.